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Abstract
Background: Developing a quantitative understanding of viral kinetics is useful for determining the pathogenesis
and transmissibility of the virus, predicting the course of disease, and evaluating the effects of antiviral therapy. The
availability of data in clinical, animal, and cell culture studies, however, has been quite limited. Many studies of
virus infection kinetics have been based solely on measures of total or infectious virus count. Here, we introduce a
new mathematical model which tracks both infectious and total viral load, as well as the fraction of infected and
uninfected cells within a cell culture, and apply it to analyze time-course data of an SHIV infection in vitro.
Results: We infected HSC-F cells with SHIV-KS661 and measured the concentration of Nef-negative (target) and
Nef-positive (infected) HSC-F cells, the total viral load, and the infectious viral load daily for nine days. The
experiments were repeated at four different MOIs, and the model was fitted to the full dataset simultaneously. Our
analysis allowed us to extract an infected cell half-life of 14.1 h, a half-life of SHIV-KS661 infectiousness of 17.9 h, a
virus burst size of 22.1 thousand RNA copies or 0.19 TCID50, and a basic reproductive number of 62.8. Furthermore,
we calculated that SHIV-KS661 virus-infected cells produce at least 1 infectious virion for every 350 virions
produced.
Conclusions: Our method, combining in vitro experiments and a mathematical model, provides detailed
quantitative insights into the kinetics of the SHIV infection which could be used to significantly improve the
understanding of SHIV and HIV-1 pathogenesis. The method could also be applied to other viral infections and
used to improve the in vitro determination of the effect and efficacy of antiviral compounds.
Keywords: Viral infectiousness, Quantification of viral dynamics, In vitro experiment, Mathematical model, Simian/
Human immunodeficiency virus
Background
Historically, the study of the highly pathogenic simian/
human immunodeficiency virus (SHIV) has provided
important information for the understanding of human
immunodeficiency virus type-1 (HIV-1) pathogenesis.
For example, it was clarified in an SHIV animal study
that co-receptor usage determined by the HIV-1 env
gene affects the virus’ cell tropism (preference for speci-
fic target cell populations), and thus its pathogenesis, in
vivo [1-3]. Furthermore, infections with highly patho-
genic SHIV strains in animal models have exhibited
stable clinical manifestations in most infected animals,
similar to an aspect of infection course in human HIV
infections [4,5]. One of the highly pathogenic SHIV
strains, SHIV-KS661, which has the env gene of HIV-1
89.6 and predominantly uses CXCR4 as the secondary
receptor for its infection [2], causes an infection that
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+ T cells of rhesus maca-
ques within 4 weeks after infection [6,7]. In observations
by our group in recent years, the intravenous infection
of rhesus macaques with SHIV-KS661 has consistently
resulted in high viremia and CD4
+ T cell depletion, fol-
lowed by malignant morbidity as a result of severe
chronic diarrhea and wasting after 6 to 18 months [8].
Despite this well-developed in vivo model, the detailed
kinetics of SHIV-KS661 remain unclear. Quantifying
and understanding viral kinetics will provide us with
novel insights about the pathogenesis of SHIV (and
HIV-1), for example, by enabling the quantitative com-
parison of the replicative capacity of different strains.
In recent years, virological data from clinical patient
studies, animal experiments, and cell culture studies
have frequently been analyzed using mathematical mod-
els. Mathematical analysis of clinical data is an increas-
ingly popular tool for the evaluation of drugs, the
elaboration of diagnostic criteria, and the generation of
recommendations for effective therapies [9-17]. Analyses
of animal and cell culture studies have revealed funda-
mental aspects of viral infections including the specifica-
tion of the half-life of infected cells and virus, the virus
burst size, and the relative contribution of the immune
response [18-29]. Important results have also been
obtained in the analysis of purely in vitro experiments.
For example, in Beauchemin et. al. [19], simple mathe-
matical models were employed to analyze the effect of
amantadine treatment on the course of experimental
infections of Madin Darby canine kidney (MDCK) cells
with influenza A/Albany/1/98 (H3N2) in a hollow-fiber
(HF) reactor. Fits of the models to the experimental
data determined that the 50% inhibitory concentration
(IC50) of amantadine for that particular strain was 0.3-
0.4 μM and found amantadine to be 56-74% effective at
blocking the infection of target cells. Thus, analyses of
experimental data using mathematical models have pro-
vided, and continue to provide, quantitative information
about the kinetics of viral infections - particularly for
HIV-1, the hepatitis C virus (HCV), and the influenza
virus - by estimating infection parameters buried within
experimental data.
Despite these successes, the available virological data,
even for in vitro experiments, have often been limited in
that many modeling analyses have been based only on
total viral load data (e.g., RNA or DNA copies, hemag-
glutination assay (HA)) [9-13,15-17,20,22,23,26,27] or
infectious viral load data (e.g., 50% tissue culture infec-
tion dose (TCID50) or plaque forming units (PFU))
[18,19,25]. Thus, while the applied mathematical models
typically depend on the interaction of many components
of the infection - including the populations of suscepti-
ble and infected cells - they are often only confronted
b yas i n g l eb i o l o g i c a lq u a n t i t y :t h et i m e - c o u r s eo ft h e
viral load. More rarely, diverse data sets including both
virus and cell measurements have been considered
[14,29-37]. Notable examples of the latter case include
the analysis of an influenza infection in a microcarrier
culture by Schulz-Horsel et al. [29], who measured and
modeled the infectious and total viral load, along with
the fraction of infected cells; and the in vivo studies of
HIV-1 dynamics following antiviral therapy by Perelson
and co-workers (e.g., [14,31]), who have considered
measurements of viral load as well as susceptible and
infected cells.
Here, we combined a relatively simple mathematical
model of SHIV infection in HSC-F cells with an in vitro
experimental system which allows for the measurement
of both total and infectious viral load and the concentra-
tion of target and infected cells. We infected HSC-F - a
CD4
+ T cell line established from cynomolgus monkey -
in vitro with SHIV-KS661 at four different multiplicities
of infection (MOI) and measured the concentration of
Nef-negative (susceptible/target) and Nef-positive
(infected/virus producing) HSC-F cells [cells/ml], and
the total [RNA copies/ml] and infectious [TCID50/ml]
viral load daily over nine days. With this abundant and
diverse data, we were able to fully parameterize the
dynamic model and determine robust estimates for viral
kinetics parameters, thus quantifying the infection cycle.
Our in vitro quantification system for SHIV-KS661
should be a valuable complement to the well-developed
in vivo model and can be used to significantly improve
the understanding of SHIV and HIV-1 pathogenesis.
Results
Mathematical model
To describe the in vitro kinetics of the SHIV-KS661
viral infection in our experimental system (Table 1), we
expanded a basic mathematical model widely used for
analyzing viral kinetics [13,17-19,27,38,39]. The follow-
ing equations are our extended model:
dx
dt
= −βxvI − dx (1)
dy
dt
= βxvI − ay (2)
dvI
dt
= pky − rIvI − rRNAvI (3)
dvNI
dt
=( 1− p)ky + rIvI − rRNAvNI (4)
where x and y are the number of target (susceptible)
and infected (virus-producing) cells per ml of medium,
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and non-infectious virus per ml of medium, respectively.
Parameters d, a, rRNA,a n db represent the death rate of
target cells, the death rate of infected cells, the degrada-
tion rate of viral RNA, and the rate constant for infec-
tion of target cells by virus, respectively. We assume
that each infected cell releases k virus particles per day
(i.e., k is the viral production rate of an infected cell), of
which a fraction p are infectious and 1-p are non-infec-
tious. Infectious virions lose infectivity at rate rI, becom-
ing non-infectious. Implicit in Eqs.(1)-(4) is the
assumption that once a cell is infected by infectious
virus it immediately begins producing progeny virus.
We also tested a variant of the model which incorpo-
rates an “eclipse” phase of infection to represent the
cell’s period of latency prior to virus production. We
found, however, that including this phase did not signifi-
cantly improve the fit of the model to the data and led
to very similar extracted parameter values (see Addi-
tional files 1, 2, 3). Therefore, in all further analyses, this
phase was omitted in favor of the simpler model formu-
lation. A schematic of our mathematical model is shown
in Figure 1.
To fit the observed viral load data - consisting of RNA
copies/ml and TCID50/ml - and to account for the par-
tial removal of cells and virus due to sampling, we
transformed Eqs.(1)-(4) into the following scaled model:
dx
dt
= −β50xv50 − dx − δx (5)
Table 1 Experimental data for the in vitro experiment
MOI Measurement day
0 1 234567 8
Concentration of Nef-negative HSC-F cells (cells/ml)
2×1 0
-3 5470829 6044623 2690861 1012828 223584 42130 58470 10386 10270
2×1 0
-4 2333804 4953074 2985268 2201172 811240 621750 60255 19998 4857
2×1 0
-5 2574201 3563431 3434160 2345412 1269216 1345728 264794 71792 127996
2×1 0
-6 3357117 2583058 4557411 35074989 1334060 1896048 1022157 307908 153360
Concentration of Nef-positive HSC-F cells (cells/ml)
2×1 0
-3 d.l.* d.l. 439139 1167172 736416 177870 41530 19614 9730
2×1 0
-4 d.l. d.l. 84732 158828 548760 878250 89745 40002 5143
2×1 0
-5 d.l. d.l. d.l. 64588 170784 574272 165206 88208 92004
2×1 0
-6 d.l. d.l. d.l. d.l. 65940 383952 347843 232092 86640
Total viral load of SHIV-KS661 (RNA copies/ml)
2×1 0
-3 9180000 331000000 2840000000 4050000000 3140000000 1120000000 154000000 20200000 5650000
2×1 0
-4 1030000 26200000 256000000 1670000000 2110000000 1740000000 609000000 134000000 19400000
2×1 0
-5 126744 4370000 51200000 489000000 1280000000 1940000000 1230000000 570000000 130000000
2×1 0
-6 10170 800536 4600000 54200000 322000000 1300000000 1210000000 603000000 275000000
Infectious viral load of SHIV-KS661 (TCID50/ml)
2×1 0
-3 40 4064 40960 81920 163840 20480 2560 160 d.l.
2×1 0
-4 d.l. 101 403 5120 16255 40960 1280 101 40
2×1 0
-5 d.l. 64 640 4064 20480 25803 5120 1280 640
2×1 0
-6 40 40 80 640 5120 1280 1280 640 1280
“d.l.” designates samples in which the concentration was below the detection limit.
Figure 1 A schematic representation of the mathematical
model. The variables x and y are the number of target and infected
cells; vI and vNI are the number of RNA copies of infectious and
non-infectious virus, respectively. Parameters d, a, rRNA, and b
represent the death rate of target cells, the death rate of infected
cells, the degradation rate of viral RNA, and the rate constant for
infection of cells by infectious virus, respectively. It is assumed that
infected cells release virus particles at a rate k, that a fraction p of
these particles are infectious (1-p are non-infectious) but lose
infectivity at a rate rI, becoming non-infectious.
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dt
= β50xv50 − ay − δy (6)
dvRNA
dt
= ky − rRNAvRNA − rcvRNA (7)
dv50
dt
= k50y − rIv50 − rRNAv50 − rcv50 (8)
where vRNA =v I+vNI is the total concentration of viral
RNA copies, v50 = avI is the infectious viral load
expressed in TCID50/ml, and a is the conversion factor
from infectious viral RNA copies to TCID50.S i n c et h e
measure of 1 TCID50 corresponds to an average of 0.68
infection events (by Poisson statistics), we have 0
<a≦1.47 TCID50 per RNA copies of infectious virus.
Parameters b50 = b/a and k50 = apk are the converted
infection rate constant and production rate of infectious
virus, respectively. At each sampling time, the concen-
tration of Nef-negative and Nef-positive HSC-F cells
must be reduced in our model by 5.5% and the viral
loads (RNA copies and TCID50) by 99.93% to account
for the experimental harvesting of cells and virus. These
losses were modeled in Eqs.(5)-(8) by approximating the
sampling of cells and virus as a continuous exponential
decay, yielding a rate of δ =0 . 0 5 7per day for cell har-
vest and rc =7 . 3 1per day for virus harvest. We found
that a model which implements the sampling explicitly,
as a punctual reduction at each sampling time, similar
to the model in [19], did not significantly improve the
quality of the fit (data not shown).
Of the seven free model parameters remaining, three
of them (d, rI, rRNA) were determined by direct measure-
ments in separate experiments described below. The
remaining four parameters (b50, a, k, k50)a l o n gw i t h1 6
initial (t=0 ) values for the variables (four at each of the
four MOI values) were determined by fitting the model
to the data as described in Methods (Tables 2 and 3).
In vitro half-lives of the SHIV-KS661 virus and HSC-F cells
The rates at which SHIV-KS661 virions lose infectivity,
rI, and the rate at which their viral RNA degrades, rRNA,
were each estimated directly in separate experiments
(Figure 2). Linear regressions were performed to fit
logvRNA(t) = logvRNA(0)-rRNAt and logv50(t) = logv50(0)-rIt
to those data, yielding values of rRNA = 0.039 per day
(95% confidence interval (95%CI): 0.013-0.065 per day)
and rI =0 . 9 3per day (95%CI: 0.44-1.4 per day). These
correspond to an infectious virion half-life of 17.9 h and
an RNA viability half-life of 17.7 d. The death rate of
target cells, d, was also estimated directly, in a mock
infection experiment where Nef-negative (target) HSC-F
cells were exposed to the culture conditions of the
experiment without virus (data not shown). A linear
regression was performed to fit logx(t) = logx(0)-(d+δ)t
to the time course data, yielding d = 0.21 per day (95%
CI: 0.18-0.27), corresponding to an average target cell
lifespan of 4.76 d (half-life of 3.30 d).
Time-course in vitro data
Time-course in vitro experimental data were collected
over nine days, consisting of the concentrations of Nef-
Table 2 Parameters values and derived quantities for the in vitro experiment
Parameter Name Symbol Unit Value 95%CI
Calculated parameters for the continuous approximation of cell and virus harvest
Harvest rate of target and infected cells δ day
-1 0.057 –
Harvest rate of total and infectious virus rc day
-1 7.31 –
Fitted parameters from separate experiments
Decay rate of uninfected cells d day
-1 0.21 0.17-0.26
Rate of virion infectivity loss rI day
-1 0.93 0.44-1.4
Degradation rate of virion RNA rRNA day
-1 0.039 0.013-0.065
Parameters obtained from simultaneous fit to full in vitro dataset
Rate constant for infections b50 (TCID50/ml·day)
-1 4.95 × 10
-5 (2.35-9.59) × 10
-5
Decay rate of infected cells a day
-1 1.18 0.85-1.26
Production rate of total virus k RNA copies·day
-1 2.61 × 10
4 (1.55-3.70) × 10
4
Production rate of infectious virus k50 TCID50·day
-1 0.22 0.12-0.40
Quantities derived from fitted values
Viral burst size (total) k/a RNA copies 2.21 × 10
4 (1.74-2.96) × 10
4
Viral burst size (infectious) k50/a TCID50 0.19 0.11-0.33
Basic reproductive number (without removal) R0 – 62.8 51.1-76.8
Basic reproductive number (with removal) R0* – 7.01 5.70-8.45
Minimum fraction of infectious virus k50/k TCID50/RNA copies 8.63 × 10
-6 (4.53-16.9) × 10
-6
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total SHIV-KS661 viral load [RNA copies/ml], and the
infectious viral load [TCID50/ml]. At each daily mea-
surement, almost all of the culture supernatant (99.93%)
was removed for viral counting; a small percentage of
cells (5.5%) were removed for counting and FACS analy-
sis, and the remaining cells were thoroughly washed and
replaced in fresh medium. The experiment was repeated
for four different values of the initial viral inoculum
(MOI). In total, we obtained 130 data points for quanti-
fying SHIV-KS661 viral kinetics in vitro (Table 1 and
Figure 3).
In examining the MOI = 2×1 0
-3 data, one can see
that the target cell population remains high (near its
initial value of approximately 6.46 × 10
6 cells/ml) until
just before the peak of the virus concentration, at which
point the target cell population decreases rapidly. The
total infected cell population, the total virus count
(RNA/ml), and the infectious virus count (TCID50/ml)
all peak around t=3days. Moreover, the rate of expo-
nential decay (downward slope) of the total virus and
the infected cell population after their respective peaks
are quite similar. This behavior is expected: since the
virus is being almost completely removed from the cul-
ture on a daily basis due to sampling and the RNA
degradation rate is very small (rRNA = 0.039 per day);
the measured RNA count of virus is nearly equal to the
total number of virus produced over the preceding day
which should be proportional to the number of cells
producing virus. Similar reasoning should apply to the
decay of infectious virus - the net infectious virus mea-
sured after one day should also be approximately pro-
portional to the number of infected cells - but the rates
appear much less closely aligned in this case, perhaps
due to larger errors in the TCID50 measurement techni-
que. Alternatively, the observed more rapid than
expected decrease of infectious virus could have a biolo-
gical cause. For instance, the co-infection of cells by
competent and defective interfering viruses at late stages
in the experiment could lead to an enhanced production
of the latter [40], thus successively reducing the fraction
of infectious particles. An increase in cell-death by-pro-
ducts could also contribute to the decline in virus infec-
tivity. In SIV and SHIV infections in vivo, a decreasing
viral infectiousness has been observed over time
Table 3 Fitted initial (t = 0) values for the in vitro experiment
Variable Unit Fitted initial value at MOI of
2×1 0
-3 2×1 0
-4 2×1 0
-5 2×1 0
-6
xj(0) cells/ml 6.55 × 10
6 6.50 × 10
6 5.82 × 10
6 4.94 × 10
6
yj(0) cells/ml 6.47 × 10
2 1.60 × 10
2 6.89 × 10
-3 0.254
vRNAj(0) RNA copies/ml 9.15 × 10
6 1.05 × 10
6 1.58 × 10
5 8.21 × 10
3
v50j(0) TCID50/ml 43.1 0.162 2.92 2.99
Figure 2 Rates of RNA degradation and loss of infectivity for
SHIV-KS661. Stock virus was incubated under the same conditions
as the infection experiments, but in the absence of cells, then
sampled every day and stored at -80°C. After the sampling, the RNA
copy number (gray circles) and 50% tissue culture infectious dose
(black circles) of the samples were measured. Linear regressions
yielded a rate of RNA degradation of rRNA = 0.039 per day and a
rate of loss of viral infectivity of rI = 0.93 per day.
Figure 3 Fits of the mathematical model to experimental data
of SHIV-KS661 in vitro. HSC-F cells were inoculated with SHIV-
KS661 24 h before t=0 , and each in vitro experimental quantity
was measured daily from t=0dt o8 d. The curves show the best-
fit of the model (Eqs.(5)-(8), lines) to the experimental data (points)
for the target cells, infected cells, and the total and infectious viral
load for the four different experiments conducted at different MOIs.
All data were fitted simultaneously as described in the text. The
fitted t=0values of each quantity are given in Table 3.
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Page 5 of 12[7,41,42], but the timescale of this decay is longer than
that observed here and likely has an in-host origin.
A comparison of the experiments at the four different
MOI values shows that a decrease in the initial viral
inoculum serves primarily to delay the course of the
infection. The target cell populations drop to approxi-
mately half of their original values at t ≈ 1.9, 2.6, 3.5
and 4.1 days, respectively, for the four experiments in
order of decreasing MOI. Similarly the peaks of the
total viral RNA occur at t ≈ 3.0, 4.0, 5.0 and 5.5 days,
respectively. The experiments at lower MOI have
slightly lower viral and infected cell peaks, but differ
from those of the experiment at MOI = 2×1 0
-3 by less
than a factor of three.
Relevant SHIV-KS661 viral kinetics measures
Having fixed the values of the rates of virion decay (rI
and rRNA) and the target cell death rate (d)u s i n gs e p a -
rate experiments, we estimated the values and 95% CI
of the four remaining unknown parameters (b50, a, k,
k50) by fitting the model in Eqs.(5)-(8) to the full in
vitro dataset simultaneously (Table 2). The death rate of
infected cells was determined to be a = 1.18 per day
(95%CI: 0.85-1.26 per day) which implies that the half-
life of infected cells (i.e., log2/a)i s14.1 h. Infected HSC-
Fc e l l sw e r ef o u n dt op r o d u c ek = 2.61 × 10
4 RNA
copies of virus per day.
From the directly fitted parameters, we also calculated
a number of important derived quantities and their 95%
CI, determined from the bootstrap fits (Table 2). One
key measurement of viral kinetics is the viral burst size,
which is the total number of virus produced by an
infected cell during its lifetime [18-20]. The total burst
size of SHIV-KS661 (including non-infectious and infec-
tious virus) is given in our model by k/a and was esti-
mated from our in vitro experiment to be 2.21 × 10
4
RNA copies. The burst size of infectious SHIV-KS661,
k50/a, was 0.19 TCID50.
To broadly characterize viral kinetics, it is instructive
t oc a l c u l a t et h eb a s i cr e p r o d u c t i v en u m b e rf o rt h es y s -
tem, which has the form R0 = b50k50x0/(a(rI+rRNA)) and
is interpreted as the number of newly infected cells
intrinsically generated by a single infectious cell at the
start of the infection [15-19,27]. The initial number of
HSC-F cells, x0, was approximately 6.46 × 10
6 cells/ml,
which, together with the values of the five estimated
parameters, yields an estimate for the basic reproductive
number of 62.8.T h i sl a r g ev a l u e( 6 2.8»1) implies that,
given a small initiating infected cell population, the
infection is overwhelmingly likely to spread to the entire
population of cells.
After the repetitive removal of cells and virus begins,
the basic reproductive number is effectively reduced,
much like the effect of quarantine on the
epidemiological measure of R0. When the effects of
removal are included in the calculation of the basic
reproductive number it has the form R0*=b50k50x0/((a
+δ)(rI+rRNA+rC)) which yields a smaller value of 7.01.
This value better characterizes the course of the infec-
tion in our system, for example, through the recursive
relation for the approximate fraction of eventually
infected cells, fI = 1- exp(-R0*f I) [43]. Using this expres-
sion, we find that the fraction of target cells at the end
of the infection (1-fI) should be 9.01 × 10
-4,w h i c h
implies an approximately final target cell concentration
is 5.87 × 10
3 cells/ml. This value agrees well with the
asymptotic concentration of Nef-negative HSC-F cells in
the MOI = 2×1 0
-3 experiment, ~1.03 × 10
4 cells/ml.
The delay of the infection precludes an estimate of the
final target cell value at smaller MOI values.
Our model formulation also enables us to determine,
albiet not fully, two interesting quantities related to the
infectiousness of SHIV-KS66 virions. Parameter p
(where 0 <p≦1) is the fraction of SHIV-KS66 virions
which are infectious at the time of production: the lar-
ger the value of p, the fewer defective virus particles are
produced by infectious cells. Parameter a is approxi-
mately the fraction of infectious virions which are mea-
sured in the TCID50 assay, i.e., it is the ratio of TCID50
viral titer (v50) to the RNA count of infectious virions
(vI). It follows from Poisson statistics that 0 <a≦1.47
TCID50 per infectious RNA copies of infectious virions.
W h i l ew ec a n n o td e t e r m i n ep and a individually in our
analysis, their product is given by k50/k = (apk)/k = ap
=8 . 6 3×1 0
-6 TCID50 per infectious RNA copies.
Because of the upper bounds on p and a,t h ev a l u eo f
their product imposes a minimum condition on each:
5.87 × 10
-6 <p≦ 1 and 8.63 × 10
-6 <a≦1.47 TCID50 per
RNA copies.
We can constrain these parameters further by consid-
ering the basic reproductive number R0 =6 2 . 8 ,w h i c h
implies that one infectious cell will infect 62.8 other
cells over the course of its infectious lifespan. Thus, one
infectious cell must produce at least 62.8 infectious vir-
ions over its lifespan, i.e., have a burst size of at least
62.8 infectious RNA copies. The burst size in infectious
virions is given by pk/a, so this requirement can be writ-
ten as pk/a ≥ R0 infectious RNA copies (or, equivalently,
p ≥ aR0/k infectious RNA copies) which, based on the
values of these quantities from Table 2 implies that p ≥
2.84 × 10
-3. Thus 2.84 × 10
-3≦p≦1, which means that at
least one in every 350 virions produced is infectious.
Since ap = 8.63 × 10
-6 TCID50 per infectious RNA
copies, it follows that 8.63 × 10
-6 <a≦3.04 × 10
-3
TCID50 per infectious RNA copies, which means that 1
TCID50 corresponds to at least 330 (1/3.04 × 10
-3) infec-
t i o u sv i r u s ,b u tp e r h a p sa sm a n ya s120, 000 (1/8.63 ×
10
-6).
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We have applied a simple mathematical model to quan-
titatively characterize the in vitro kinetics of SHIV-
KS661 virus infection in HSC-F cell cultures, leveraging
experimental data for total and infectious viral load,
along with target and infected cell dynamics, to fully
parameterize the system. Specifically, we determined
values for the rate of loss of infectivity and the RNA
degradation rate of SHIV-KS661, the target and infected
HSC-F cell half-life, the rate constant for infection of
target cells and the infectious and total viral production
rates of infected cells. From these fundamental quanti-
ties, we also estimated a number of important derived
quantities, including the burst size of an infected cell
and the basic reproductive number. Additionally, by
measuring both the total and infectious viral load within
t h ec o n t e x to fam a t h e m a t i c a lm o d e lw ew e r ea b l et o
provide a lower bound for the proportion of infectious
virions produced by infected cells.
We estimated the half-life of SHIV-infected HSC-F
cells to be 14.1 h. In clinical studies of patients or ani-
mals, it is extremely difficult to continuously measure
the number of infected cells during infection. This is
because the amount of infected cells in peripheral blood
(PB) is very small. For example, in HIV-1 infected
patients, there are only about 10
2 infected cells per 10
6
peripheral blood mononuclear cells at their set point
[14]. Thus, measuring the number of infected cells in
PB during the early phase of infection is technically dif-
ficult. In HIV-1 humanized mice, infected cells in PB
are not detectable even during the acute phase when
80-90% of target cells in the spleen and lymph nodes
are infected (K. Sato and S. Iwami, unpublished data).
For this reason, the death rate of infected cells in vivo
has primarily been estimated from the viral load decay
(or the decay of infectious virus) after the peak of an
acute infection [11,16,17,20,27] or after antiviral drug
administration [10,14,15,22]. The maximum half-lives of
HIV-1 and SIV-infected cells were both initially esti-
mated - by analysis of in vivo viral decay under antiviral
therapy - to be ~24 h [14,27], but drug combinations
with higher efficacy have reduced the estimates to ~17
and ~11 h, respectively [12,22,44]. Our in vitro estimate
of the half-life, based on direct observations of Nef-posi-
tive cell decay, agrees well with these indirect in vivo
measures, despite the absence of immune effects.
We determined an SHIV-KS661 viral burst size of
2.21 × 10
4 RNA or 0.19 TCID50 for HSC-F cells. Cur-
rent estimates of viral burst size in the literature rely on
inhibiting multiple rounds of infection by antiviral
drugs, washouts of infected cells, serial dilutions of
infected cells, or infection by single-cycle virus
[11,20,21,45,46]. The inhibition of the multiple rounds
of infection, however, can introduce additional con-
founding factors on the viral burst size as discussed in
[20]. Here, we have calculated the burst size of SHIV-
KS661 in HSC-F cells indirectly by estimating the viral
production rate and the average lifespan of infected cells
over the course of a typical infection. Our estimate is
quite close to the ~5 × 10
4 RNA value determined in
recent SIV single-cycle virion experiments in vivo [20],
which, notably, was 10-100 times higher than most pre-
viously measured values. We also calculated a basic
reproductive number for SHIV-KS661 in HSC-F cell
cultures as approximately 62.8 for the initial stages of
the infection and approximately 7.01 for the entire
course, when the effects of manual removal of virus and
cells are included. The latter value implies that reducing
viral growth by about 85.7% for the entire course with
antiviral intervention, for example, would prevent viral
spread in vitro given the daily sampling.
It is widely believed that retroviruses are predomi-
nantly defective, with less than 0.1% of virions in plasma
or culture media being infectious [47-49]. On the other
hand, it has recently been suggested that HIV-1 virions,
for example, are inherently highly infectious, but that
slow viral diffusion in liquid media and rapid dissocia-
tion of virions from cells severely limit infections in cul-
tures (i.e., in assays measuring infectivity) [50,51]. On
b o t hs i d e so ft h i sd e b a t e ,h o w e v e r ,s t u d i e sh a v eo f t e n
relied on measurements of the proportion of infectious
virus in stock samples, or on measurements of the infec-
tious/non-infectious ratio over the course of an in vitro
experiment. These direct measurements of the infectiv-
ity ratio in a virus sample are necessarily confounded by
a continuous loss of infectious virus, driven by thermal
deactivation and RNA degradation and, as such, these
analyses cannot address the question of what fraction of
virus are infectious at the time of production. Here, we
have estimated the production rates of both infectious
and non-infectious virus, allowing for a novel quantita-
tive specification of the fraction of newly generated
virus that is infectious. This fundamental quantity is
important in understanding the role and influence of
defective virus particles [48-50,52]; and, to our knowl-
edge, this has not been measured before for any virus
strain. We determined the theoretical minimum value
for the proportion of infectious virions among newly
produced virus, p,t ob e8.62 × 10
-6, by calculating the
ratio of the infectious to total viral production rates k50/
k. The ratio of the production rates, however, is actually
p multiplied by a,w h e r ea is the conversion factor
from RNA count of infectious virions to TCID50 (i.e.,
roughly the fraction of infectious virions that are actu-
ally measured in a TCID50 titration assay). Therefore,
since a is likely much less than one, the proportion of
infectious virus is likely much higher. In fact, using the
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the minimum value of p is approximately 2.84 × 10
-3,
meaning that at least 1 of every 350 virions produced is
infectious. Determining this quantity is particularly
important in determining the true efficiency of infec-
tious virus replication. In previous publications [53,54],
it was reported that vif-deficient HIV-1 showed
decreased production of infectious virus due to the inhi-
bition of the viral replication process by host factors
such as APOBEC3 protein. Our method suggests a
novel and more reliable way to determine the effect of
the host-viral protein interaction on infectious viral
replication.
In another aspect of viral infectivity, we found that the
SHIV-KS661 virion infectious half-life at 37°C was 17.9
h. While this quantity is vital for understanding viral
dynamics in vitro, and represents an important, strain-
specific physical property of the virion, it is unlikely to
strongly influence in vivo dynamics, due to the extre-
mely high physical clearance rate in the blood (virion
half-lives are on the order of minutes) [23].
Conclusions
To conclude, by using a simple mathematical model for
SHIV-KS661 infection on HSC-F cells and an abundant,
diverse experimental dataset, we have been able to reli-
ably estimate the parameters characterizing cell-virus
interactions in vitro. Based on these estimated para-
meters, we have provided a quantitative description of
SHIV-KS661 kinetics in HSC-F cell cultures which is
consistent with previous studies of lentiviruses and pro-
vides a number of novel quantities. Most notably, our
analysis provides an estimate of the minimum fraction
of infectious virus produced by an infected cell. Our
improved method for quantifying viral kinetics in vitro -
which depends crucially on detailed time-course infor-
mation about the infection of cells in addition to that of
virus (both total particle count and infectious titer) -
could be applied to other viral infections. The method
could likely improve the understanding of the differ-
ences in replication across different strains [25,55] or
between complete and protein-deficient viruses [53,54];
the differences in viral pathogenesis [6]; and the effects
of anti-viral therapies [9,13]. Quantifying the in vitro
viral kinetics for viruses such as HCV [56,57], for which
a convenient animal experimental model has not been
established, is of particular interest. Since the method
presented here allows for the complete resolution of all
viral kinetic parameters, it also enables the identification
of the mechanisms of action for new antiviral com-
pounds. Indeed, repeating the experimental infection
under various antiviral concentrations would distinctly
reveal which parameters (e.g., half-life of infected cells,
infectious viral burst size) are affected by the antiviral
and to what extent. Furthermore, the inhibitory concen-
tration of the compound could be independently deter-
mined for each parameter. Thus, our synergistic
approach, combining experiments and mathematical
models, has broad potential applications in virology.
Methods
Virus and cell culture
T h ev i r u ss t o c ko fS H I V - K S 6 6 1[ 5 ]w a sp r e p a r e di na
CD4
+ human T lymphoid cell line, M8166 (a subclone
of C8166) [58]. The stock was stored in liquid nitrogen
until use. Establishment of the HSC-F cell line has been
previously described [59]. This is a cynomolgous mon-
key CD4
+ T-cell line from fetal splenocytes that were
immortalized by infection with Herpesvirus saimiri sub-
type C. The cells were cultured in RPMI-1640 medium
supplemented with 10% fetal calf serum at 37°C and 5%
CO2 in humidified condition.
In vitro experiment
Each experiment was performed using 2 wells of a 24-
well plate with a total suspension volume of 2 ml (1 ml
per well) and an initial cell concentration of 6.46 × 10
6
cells/ml in each well. Because the initial cell concentra-
tion is close to the carrying capacity of 24-well plates
and the doubling time of HSC-F cells is not short, the
population of target cells, in the absence of SHIV-KS661
infection, changes very little on the timescale of our
experiment. We therefore neglected the effects of poten-
tial regeneration of HSC-F cells when constructing the
mathematical model.
Cultures of HSC-F cells were inoculated at different
MOIs (2.0 × 10
-3,2 . 0×1 0
-4,2 . 0×1 0
-5, 2.0 × 10
-6; MOI
= TCID50/cell) of SHIV-KS661 and incubated for 4 h at
37°C. After inoculation, cells were washed three times to
remove the infection medium and placed in fresh media.
Subsequently, the culture supernatant was harvested
daily for 9 d, along with a small fraction of the cells
(5.5%) for counting of viable and infected cells. The
remaining cells were then gently washed three times
and placed in a fresh, virus-free, medium. Separate
experiments (not shown) determined that free virus was
not completely removed, but that virus concentration in
the supernatant dropped to 0.066% of its value prior to
this sampling and washing procedure. Harvested culture
supernatants were frozen and stored at -80°C until they
were assayed via RT-PCR and TCID50 titration, as
described below.
Count of viable and infected cells
Virus infection of the HSC-F cells was measured by
FACS analysis using markers for intracellular SIV Nef
antigen expression. The counts of total and viable cells
were first determined using a cell counting chamber
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staining. Viable HSC-F cells (gated by forward- and
side-scatter results) were examined by flow cytometry to
measure the intracellular SIV Nef antigen expression
(see Figure 4). Cells were permeabilized with detergent-
containing buffer (Permeabilizing Solution 2, BD Bios-
ciences, San Jose, CA). The permeabilized cells were
stained with anti-SIV Nef monoclonal antibody (04-001,
Santa Cruz Biotechnology, Santa Cruz, CA) labeled by
Zenon Alexa Fluor 488 (Invitrogen, Carlsbad, CA), and
analyzed on FACSCalibur (BD Biosciences, San Jose,
CA).
Total and infectious viral load quantification
We followed the kinetics of both the total and infectious
SHIV-KS661 viral load. The total viral load was mea-
sured with a real-time PCR quantification assay, as
described previously [5], with minor modifications.
Briefly, total RNA was isolated from the culture super-
natants (140 μl) of virus-infected HSC-F cells with a
QIAamp Viral RNA Mini kit (QIAGEN, Hilden, Ger-
many). RT reactions and PCR were performed by a
QuantiTect probe RT-PCR Kit (QIAGEN, Hilden, Ger-
many) using the following primers for the gag region;
SIV2-696F (5’-GGA AAT TAC CCA GTA CAA CAA
ATAGG-3’) and SIV2-784R (5’-TCT ATC AAT TTT
ACC CAGGCA TTT A-3’). A labeled probe, SIV2-731T
(5’-Fam-TGTCCA CCT GCC ATT AAG CCC G-
Tamra-3’), was used for detection of the PCR products.
These reactions were performed with a Prism 7500
Sequence Detector (Applied Biosystems, Foster City,
CA) and analyzed using the manufacturer’s software.
For each run, a standard curve was generated from dilu-
tions whose copy numbers were known, and the RNA
in the culture supernatant samples was quantified based
on the standard curve. The infectious viral load was
measured by TCID50 assay in HFC-S cell cultures using
96-well flat bottom plates at cell concentrations of 1.0 ×
10
6 cells/ml. The titer of the virus was determined as
described by Reed and Muench [60].
Rate of RNA degradation and loss of infectivity for SHIV-
KS661 in the culture condition
The RNA degradation and thermal deactivation of
SHIV-KS661 was measured by incubating 4 ml of stock
virus, without cells, in a 35 mm Petri dish under the
same conditions as the infection experiments (in RPMI-
1640 medium supplemented with 10% fetal calf serum
at 37°C and 5% CO2 in humidified condition). Aliquots
of the stock (500 μl) were sampled every day from day 0
to day 5 and stored at -80°C (see Figure 2). The RNA
copy number and 50% tissue culture infectious dose of
the samples were measured as described above.
Mathematical model and fitting
We simultaneously fit Eqs.(5)-(8) to the concentration of
Nef-negative and Nef-positive HSC-F cells and the
infectious and total viral loads at four different MOIs
(Figure 3) using nonlinear least-squares regression
(FindMinimum package of Mathematica7.0)w h i c h
minimizes the following objective function:
SSR =
4 
j=1

9 
i=1

logxj(ti) − logxe
j(ti)
2
+
9 
i=1

logyj(ti) − logye
j(ti)
2
+
9 
i=1

logvRNAj(ti) − logvRNA
e
j(ti)
2
+
9 
i=1

logv50j(ti) − logv50
e
j(ti)
2

where xj(ti), yj(ti), vRNAj(ti),a n dv50j(ti) are the model-
predicted values for Nef-negative cells, Nef-positive
cells, total RNA viral load and infectious (TCID50)v i r a l
load, given by the solution of Eqs.(5)-(8) at measure-
ment time ti (ti = 0, 1, 2, ..., 8 d). Index j is a label for
the MOI of the four experiments (i.e., for MOI: 2.0 ×
10
-3, 2.0 × 10
-4, 2.0 × 10
-5, and 2.0 × 10
-6). The variables
with superscript “e“ are the corresponding experimental
measurements of those quantities. Note that the HSC-F
cells were inoculated with SHIV-KS661 24 h before t=
0. Experimental measurements below the detection limit
(marked “d.l.” in Table 1) were excluded when comput-
ing the SSR. Alternative fits with various weights on the
infectious viral load to account for larger errors in the
TCID50 value [61], were also performed, but these did
not significantly alter the extracted parameter values
(Additional files 4, 5, 6, 7, 8, 9). To derive the 95% con-
fidence interval for each parameter, we employed the
(i)  (ii)
(iii) (iv)
S
S
C
c
o
u
n
t
s
FSC Nef
1  R 
1  R 
Figure 4 Flow cytometry analysis of HSC-F cells stained with
Nef antigen. Representative data at 1 day (i and ii) and 5 days (iii
and iv) post-inoculation with SHIV-KS661 at an MOI of 2 × 10
-5 are
shown. The viable cell population, gated by the data of forward
(FSC) and side scatter (SSC) (region surrounded with a solid line in
(i) and (iii), respectively), was fractionated by Alexa-488-labeled Nef
staining in (ii) and (iv). The counts within the M1 regions and the
remaining parts of the total counts are defined as the fraction of
Nef- positive (infected) and Nef-negative (target) cells, respectively.
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using 256 replicates of the four data sets and calculating
the 2.5 and 97.5 percentiles.
Additional material
Additional file 1: Fit of a mathematical model which includes an
eclipse phase of infection to experimental data of SHIV-KS661 in
vitro. Testing a variant of the model which incorporates an “eclipse”
phase of infection to represent the cell’s period of latency prior to virus
production (see Additional file 2 for more detailed information).
Additional file 2: Additional documentation for Additional files 1.
Detailed explanation of mathematical models used in Additional files 1.
Additional file 3: Table for estimated parameters in Additional files
1. Parameters values, initial values and derived quantities for the in vitro
experiment with eclipse model.
Additional file 4: Fit of the mathematical model with SSR
W (W=
0.0001) to experimental data of SHIV-KS661 in vitro (a). Fitting with
weight of W = 0.0001 on the infectious viral load to account for larger
errors in the TCID50 value (see Additional file 8 for more detailed
information).
Additional file 5: Fit of the mathematical model with SSR
W (W=
0.1) to experimental data of SHIV-KS661 in vitro (b). Fitting with
weight of W = 0.1 on the infectious viral load to account for larger errors
in the TCID50 value (see Additional file 8 for more detailed information).
Additional file 6: Fit of the mathematical model with SSR
W (W=1 0 )
to experimental data of SHIV-KS661 in vitro (c). Fitting with weight of
W=1 0on the infectious viral load to account for larger errors in the
TCID50 value (see Additional file 8 for more detailed information).
Additional file 7: Fit of the mathematical model with SSR
W (W=
10000) to experimental data of SHIV-KS661 in vitro (d). Fitting with
weight of W = 10000 on the infectious viral load to account for larger
errors in the TCID50 value (see Additional file 8 for more detailed
information).
Additional file 8: Additional documentation for Additional files 4, 5,
6, 7. Detailed explanation of mathematical models used in Additional
files 4, 5, 6, 7.
Additional file 9: Table for estimated parameters in Additional files
4, 5, 6, 7. Parameters values and derived quantities for the in vitro
experiment with various SSR
Ws.
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